5.67
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional
What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader By Investing.com - Investing.com South Africa
First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan
Monte Rosa (GLUE) Soars 13.58% in Three Days, Hits 2025 High - AInvest
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Monte Rosa Therapeutics Inc (GLUE) Stock: A Year of Market Movement, Down and Up - investchronicle.com
How Monte Rosa Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - beatles.ru
What makes Monte Rosa Therapeutics Inc. stock price move sharplyFree Consultation - Newser
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention2x 3x 5x Pick Alert - Newser
With surface mimicry, molecular glues shed hairpin need - BioWorld MedTech
Monte Rosa Therapeutics (GLUE) Soars 4.55% on Clinical Trial Progress - AInvest
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):